StockData
GeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS) stock

WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$47.29−3.73 (-7.31%)

Close on Nov 17, 2026Market cap $1.41BP/E –Yield –

GeneDx operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

GeneDx's operating income for the twelve months ending Jun 30, 2026 was -$92.41M, down 1800.3% year over year. For fiscal 2025 it was -$13.08M. The highest annual figure on record is -$13.08M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$13.08M–
FY2024Dec 31, 2024-$23.21M–
FY2023Dec 31, 2023-$180.60M–
FY2022Dec 31, 2022-$667.65M–
FY2021Dec 31, 2021-$446.15M–
FY2020Dec 31, 2020-$241.99M–
FY2019Dec 31, 2019-$30.41M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.46M-294.8%
Q1 FY2026Mar 31, 2026-$57.47M–
Q4 FY2025Dec 31, 2025-$14.24M-261.7%
Q3 FY2025Sep 30, 2025-$3.25M–
Q2 FY2025Jun 30, 2025$8.96M–
Q1 FY2025Mar 31, 2025-$4.55M–
Q4 FY2024Dec 31, 2024$8.81M–
Q3 FY2024Sep 30, 2024-$7.78M–
Q2 FY2024Jun 30, 2024-$10.58M–
Q1 FY2024Mar 31, 2024-$13.66M–
Q4 FY2023Dec 31, 2023-$25.64M–
Q3 FY2023Sep 30, 2023-$42.97M–
Q2 FY2023Jun 30, 2023-$51.62M–
Q1 FY2023Mar 31, 2023-$60.36M–
Q4 FY2022Dec 31, 2022-$324.88M–
Q3 FY2022Sep 30, 2022-$90.82M–
Q2 FY2022Jun 30, 2022-$162.65M–
Q1 FY2022Mar 31, 2022-$89.31M–
Q4 FY2021Dec 31, 2021-$115.78M–
Q3 FY2021Sep 30, 2021-$88.26M–
Q2 FY2021Jun 30, 2021-$45.45M–
Q1 FY2021Mar 31, 2021-$196.66M–
Q4 FY2020Dec 31, 2020-$125.05M–
Q3 FY2020Sep 30, 2020-$56.02M–
Q2 FY2020Jun 30, 2020-$34.16M–
Q1 FY2020Mar 31, 2020-$26.77M–

More GeneDx figures

See a number that looks wrong?